Emyria to participate in Foundry Builders Program

Latest News

Clinical drug development and care delivery company Emyria (ASX:EMD) has announced it has been invited to participate in the second cohort of Palantir’s Foundry Builders Program.

Under the program, Foundry is provided to emerging companies connected to Palantir alumni under a markedly reduced subscription model.

The Palantir Foundry platform creates a central operating system for their data. Palantir Foundry is designed to scale with increasing complexity, meaning it can support companies as they grow while powering data-driven decision-making.

Emyria CEO and managing director Dr Michael Winlo said, “We’re delighted to be selected to be part of the global Palantir ecosystem and leveraging one of the world’s most sophisticated and powered data platforms for our proprietary Real-World Evidence.

"Real-World Evidence (RWE) is being increasingly used by major global drug regulators, like the FDA, to evaluate the safety and efficacy of new treatments. Palantir Foundry greatly improves our ability to secure, integrate, generate and analyse our Real-World Evidence - both internally and with our global partners - meaning we can deliver on our mission to develop new treatments and improve patient care, faster.

"By using Palantir Foundry, we can generate dose-response insights and clinical decision support tools using advanced statistical and machine learning algorithms. We are also able to capture all relevant intellectual property related to our research while securely protecting patient privacy."

Emyria said its growing real-world evidence asset now covers detailed and longitudinal health outcome data for more than 5,000 patients with complex medical conditions and receiving unregistered treatments. The company said it provides unique dose-response insights and intellectual property that supports its active and developing drug development programs.